Genflow Biosciences has entered a collaboration with Acuitas Therapeutics to use Acuitas' lipid nanoparticle (LNP) delivery platform for Genflow's proprietary SIRT6 mRNA payload. This partnership aims to enhance the delivery of gene therapies targeting age-related diseases by leveraging Acuitas' expertise, which supported major mRNA Covid-19 vaccines. The collaboration is fully funded by Acuitas, with no cost or shareholder dilution for Genflow, and focuses initially on preclinical evaluation. The data generated will guide future optimization and potential licensing deals, marking a significant step in developing Genflow's SIRT6 platform.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
